Development and Phase III trial results of levacetylleucine for ataxia-telangiectasia

Michael Leo Strupp, MD, FRCP, FANA, FEAN, Ludwig Maximilian University of Munich, Munich, Germany, discusses the development of levacetylleucine for cerebellar diseases, sharing findings from a Phase III (NCT06673056) trial in ataxia-telangiectasia. Prof. Strupp discusses the development of this agent, findings from animal studies, and encouraging data from the Phase III trial. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.